VBT was aware of a number of ongoing studies in skin and skin structure infections, thus patient enrollment would potentially be affected by competing trials. Therefore, it was imperative that both our Sponsor and our internal team generate enthusiasm for this particular protocol. We began by enabling a comprehensive and targeted feasibility study to identify and evaluate upcoming competing studies, followed by an educative session with the Investigators on the biologic attributes of the study drug specifically with regard to its rapid bacteriacidal activity, potentially faster rates of resolution, and its potential to limit the development of resistance due to its multiple mechanisms of action. And finally, we recommended that the Sponsor offer more competitive Investigator grants. All these proactive steps resulted in targeted high enrollment rates for the majority of participating research sites.

Executive Snapshot

A sponsor conducting a Phase III infectious disease trial faced significant enrollment pressure from multiple competing studies targeting the same patient population.

Rather than responding by replacing sites or opening additional locations, Vantage BioTrials (VBT) developed a targeted enrollment-risk strategy combining competitive intelligence, site-specific intervention planning, investigator engagement and optimized site support.

Result: 85% of participating sites met or exceeded their enrollment targets and no site was withdrawn because of poor recruitment performance.

The Challenge

The study was being conducted in a highly competitive clinical research environment involving several concurrent trials for skin and skin structure infections. Participating sites were competing for a limited pool of eligible patients while investigators had multiple protocols from which to choose.

This created three interrelated risks for the sponsor:

• Slower-than-planned enrollment and potential pressure on critical study milestones
• Reduced investigator attention and site commitment
• Additional costs associated with replacement sites, extended timelines or corrective recruitment initiatives

The sponsor needed more than conventional site activation and follow-up. It required a strategy that could identify where enrollment pressure was most likely to occur and address the underlying causes before site performance deteriorated.

Vantage BioTrials’ Tailored Solutions

Vantage BioTrials worked with the sponsor to introduce a targeted enrollment-performance model based on four coordinated interventions.

1. Competitive-trial and enrollment-risk mapping

Vantage BioTrials assessed active and upcoming competing studies within the indication and evaluated their potential effect on individual sites and geographic markets.

The assessment considered factors such as competing protocol availability, target patient overlap, investigator interest, expected enrollment capacity and the relative operational burden of the sponsor’s study. This produced a more realistic enrollment forecast and allowed higher-risk sites to be identified before recruitment performance declined.

2. Site-specific engagement planning

Rather than applying the same recruitment strategy across every site, Vantage BioTrials helped prioritize interventions based on each site’s circumstances, capabilities and competitive environment.

Sites received focused support based on emerging performance indicators, allowing the sponsor and Vantage BioTrials to direct attention where it could have the greatest effect.

3. Investigator-focused scientific positioning

Vantage BioTrials collaborated with the sponsor to develop targeted educational sessions that clearly communicated the investigational product’s scientific and potential clinical differentiation, including:

• Rapid bactericidal activity
• Potential for faster clinical resolution
• Multiple mechanisms of action intended to help limit the development of antimicrobial resistance

The objective was not simply to repeat protocol training. It was to provide investigators with a compelling scientific rationale for prioritizing the study when several competing trials were available.

4. More competitive site support

Vantage BioTrials reviewed the investigator-grant structure and recommended adjustments to better reflect the work required of sites and the competitive recruitment environment.

This helped remove a potential barrier to participation while reinforcing the sponsor’s commitment to a productive, long-term relationship with its investigators.

Results

The integrated strategy strengthened investigator engagement, stabilized site performance and maintained enrollment momentum in a highly competitive environment.

• 85% of participating sites met or exceeded their enrollment targets
• No sites were withdrawn because of poor enrollment performance
• Enrollment velocity among targeted at-risk sites improved by an estimated 20% within three months of implementing the intervention strategy
• The sponsor avoided activating an estimated two to three replacement sites, preventing additional start-up costs and operational disruption
• The study remained within approximately four weeks of its planned enrollment-completion milestone, despite the intensity of competing trials
• Avoided site replacement and extended study-management activities represented an estimated US$250,000 in protected costs
• Site-specific enrollment interventions were developed and initiated within an average of 10 business days after a performance risk was identified

By improving the performance of the existing site network, Vantage BioTrials helped the sponsor preserve investigator relationships, avoid unnecessary site expansion and protect critical development timelines.

Why This Matters to Sponsors

Enrollment challenges are rarely solved by increasing the frequency of status meetings or adding more sites after performance begins to decline. They require early risk detection, direct access to experienced decision-makers and the flexibility to design interventions around the realities of each study.

As a specialized CRO, Vantage BioTrials combines senior-level involvement with tailored, data-informed solutions. This enables sponsors to identify execution risks earlier, make decisions more quickly and avoid the layers of escalation that can delay corrective action within conventional outsourcing models.

The same approach can be applied across a sponsor’s clinical development portfolio to strengthen site selection, enrollment planning, operational governance and inspection readiness from one program to the next.

Key Takeaway

A CRO should do more than report that enrollment is behind plan. It should identify why performance is changing, determine where intervention will have the greatest impact and implement a practical strategy before the delay affects critical development milestones.

Vantage BioTrials helps sponsors translate clinical strategy into disciplined execution through proactive risk management, senior-level oversight and solutions designed around the needs of each program.

Planning an upcoming clinical program or facing enrollment pressure?

Contact Vantage BioTrials about building enrollment resilience into your study strategy.

Protecting Phase III Data Integrity

How an early operational risk assessment prevented unintentional unblinding

Study at a Glance

During an early operational review of a Phase III gastrointestinal trial, Vantage BioTrials identified a potentially study-critical vulnerability. The investigational product and comparator could not be fully blinded and therapeutic drug monitoring requirements differed across participating institutions.

At several sites, pharmacists or treating physicians were required to review drug concentration results as part of routine patient management. Without a clearly separated operating model, treatment allocation or concentration data could inadvertently reach blinded investigators, study coordinators or outcome assessors.

An unblinding event at even one high-enrolling site could introduce bias, trigger protocol deviations, require retrospective data-impact assessments and raise questions about the reliability of efficacy or safety results. The protocol established the requirement to preserve the blind but did not fully address how each institution could achieve this within its existing workflows.

Vantage BioTrials’ Strategic Insight

Vantage BioTrials recognized that a standardized study-wide instruction would not adequately control the risk. Each institution had different pharmacy structures, laboratory reporting processes, electronic access permissions and clinical communication pathways.

Rather than force every site into a rigid process, Vantage BioTrials established a common control framework that could be adapted locally while maintaining consistent study-wide safeguards. The solution drew on lessons from a previously completed study with similar design characteristics and was implemented before site activation and patient enrollment.

The Vantage BioTrials Solution

From protocol requirement to executable site controls

Measurable outcomes

The strategy allowed sites to meet therapeutic drug monitoring requirements while maintaining a clear separation between blinded and unblinded activities. By resolving the vulnerability before enrollment, the sponsor avoided the need for reactive remediation, retrospective impact assessments and potential questions regarding the usability of affected participant data.

Why This Matters to Sponsors

Lean biotech teams depend on their CRO to identify risks that are not fully resolved by protocol language. VBT does not wait for an issue to become a deviation before addressing it. By bringing senior clinical operations and quality expertise into study planning, VBT helps sponsors translate complex protocols into practical operating models that sites can execute consistently.

Is your protocol operationally executable at every site?

Contact Vantage BioTrials about your upcoming clinical program.

The Challenge

A biotechnology sponsor conducting a Phase II trial in patients with acute variceal bleeding faced a significant enrollment and evaluability risk.

Because patients required urgent medical intervention, potentially eligible participants frequently entered the hospital through emergency departments or other acute-care units. By the time the research team was notified, medically necessary non-study therapies may already have been administered, making the patient ineligible under the protocol.

The underlying risk was therefore not limited to recruitment performance. It existed within the patient’s journey through the hospital, before the individual reached the research team.

The Operational Insight

Vantage BioTrials mapped how potential participants moved through emergency medicine, gastroenterology, hepatology, critical care, and research services.

This assessment identified the critical failure point: the interval between initial presentation, clinical assessment, treatment decisions, and notification of study personnel.

Rather than relying solely on conventional site recruitment tactics, VBT developed a cross-department strategy designed to enable earlier identification and rapid research-team notification where clinically appropriate, without delaying or interfering with necessary patient care.

The Vantage BioTrials Approach

Vantage BioTrials implemented four integrated operational controls:

Strategic site selection
Sites were evaluated not only on access to eligible patients but also on their ability to coordinate care and communicate across the clinical departments involved in the patient pathway.

Cross-department training
Training extended beyond investigators and study coordinators to emergency department personnel and other frontline healthcare professionals involved in initial patient assessment and treatment.

Site-specific referral pathways
Each site developed a customized plan defining patient-identification procedures, escalation pathways, departmental responsibilities, and rapid notification processes.

Point-of-care eligibility tools
Concise reference cards summarized critical eligibility criteria and provided direct contact information for study coordinators and investigators. These tools were distributed across relevant departments to support timely identification and referral.

All training and site-specific referral plans were completed before the applicable sites began enrollment.

The Outcome

• 100% of participating sites completed eligibility and referral-pathway training before activation.
• 100% of participating sites implemented site-specific referral plans before enrolling their first patient.
• Zero major protocol deviations related to eligibility or administration of protocol-disqualifying therapies were reported during study conduct.

The approach established consistent operational controls across participating institutions, reduced preventable eligibility risks, and protected patient evaluability.

The Vantage BioTrials AdVantage

Complex enrollment problems are not always solved by adding sites or increasing recruitment spending. In acute-care studies, the decisive risk may occur before the research team even knows that a potential participant has arrived.

Vantage BioTrials applies Quality by Design to real-world patient pathways, identifying execution risks early and implementing practical, site-specific solutions that protect eligibility, data quality, and study timelines.

Facing a clinical trial challenge that conventional approaches have not solved? 

Contact Vantage BioTrials about your study.

At a Glance

Operational risk: Dependence on a single investigational product manufacturing source, combined with limited imaging availability, threatened participant retention, enrollment, and study timelines.

Intervention: Vantage BioTrials anticipated the supply risk during study planning, escalated it when batch-release failures occurred, and led an integrated mitigation strategy involving second-source qualification, imaging-capacity assessment, participant-scheduling controls, and enhanced operational governance.

Sponsor benefit: An additional manufacturing source was qualified and activated within approximately 7 weeks, increasing production flexibility, reducing single-source dependency, and allowing the study to continue without a prolonged enrollment suspension.

The Challenge: A Critical Dependency Identified Before It Disrupted the Study

During the planning of a radiopharmaceutical clinical trial conducted at two specialized imaging sites, Vantage BioTrials identified investigational product manufacturing capacity and availability as material risks to study execution.

The initial operating model relied primarily on a single manufacturing source. Because the investigational product had to be manufactured, quality-control tested, released, administered, and imaged within tightly coordinated timeframes, a disruption at any point in that pathway could result in a cancelled participant visit.

Vantage BioTrials documented the single-source dependency during study planning and recommended that contingency manufacturing capacity be evaluated. At study initiation, however, the Sponsor assessed the likelihood of a significant supply interruption as low, and the study proceeded under the original manufacturing model.

The risk subsequently materialized.

During study conduct, investigational product could not be released on four separate occasions at one participating site because the manufactured batches did not meet applicable release requirements or could not be released within the required operational window. These events resulted in 3 participant withdrawals, the rescheduling of 4 participant visits, delayed imaging procedures, additional site burden, and increasing pressure on the enrollment timeline.

The manufacturing interruptions also exposed a second operational constraint: imaging capacity.

Although investigational product production was available weekly, scanner access was limited to narrow, site-specific scheduling windows. Participant availability, manufacturing slots, quality-control release, product administration, and imaging capacity therefore had to align on the same day. The study did not simply have a manufacturing problem, it had an interconnected capacity-management problem spanning several operational functions.

Vantage BioTrials’ Response: Moving from Event Management to Controlled Risk Mitigation

Rather than managing each failed release as an isolated scheduling issue, Vantage BioTrials escalated the recurring events as a systemic risk to study continuity.

Vantage BioTrials led a cross-functional impact assessment involving the Sponsor, manufacturing and quality representatives, nuclear medicine personnel, imaging teams, and participating sites.

The assessment examined:

        §   The causes and operational consequences of the four release interruptions;

        §   The study’s dependency on the primary manufacturing source;

        §   The relationship among manufacturing, quality-control release, participant dosing, and imaging windows;

        §   Available production and imaging capacity at both participating sites;

        §   Participant eligibility and protocol-window implications;

        §   The likelihood and potential impact of additional disruptions; and

        §   The feasibility of establishing an alternative manufacturing pathway.

The assessment confirmed that continued dependence on a single manufacturing source created an unacceptable residual risk to participant retention and study timelines. Vantage BioTrials recommended activation of a second manufacturing facility located at the other participating site and presented the Sponsor with a controlled mitigation plan.

Establishing an Additional Manufacturing Source

Vantage BioTrials coordinated the operational workstream required to qualify and integrate the second facility into the study. Activities included, as
applicable:

§    Defining facility-readiness and study-specific qualification requirements;

§    Coordinating the collection and review of manufacturing, quality, and release documentation;

§    Assessing site infrastructure, production capacity, and quality-control capabilities;

§    Evaluating the regulatory and study-document implications of the proposed change;

§    Supporting quality-agreement and responsibility-alignment activities;

§    Coordinating updates to applicable study plans, manuals, instructions, and training;

§    Confirming readiness across manufacturing, pharmacy, radiation-safety, clinical, and imaging personnel; and

§    Tracking activation activities, dependencies, owners, and escalation points through completion.

The second manufacturing facility was qualified and operationally integrated within approximately 7 weeks of Sponsor authorization.

This created an alternative production pathway, reduced dependence on the original facility, and provided greater flexibility in assigning participants to available manufacturing and imaging windows.

Integrating Imaging Capacity into Operational Planning

Vantage BioTrials also determined that adding manufacturing capacity alone would not resolve the underlying execution risk. Scanner availability had to be managed as part of the same operational pathway.

Vantage BioTrials completed site-specific capacity assessments that mapped:

§    Weekly manufacturing availability;

§    Quality-control testing and anticipated release timing;

§    Product administration requirements;

§    Scanner availability and protected imaging windows;

§    Participant travel and scheduling considerations;

§    Protocol-defined visit windows; and

§    Site staffing and departmental dependencies.

Based on these assessments, Vantage BioTrials worked with the sites and Sponsor to implement a more structured scheduling model. Manufacturing and imaging availability were reviewed together before participant appointments were finalized, and potential conflicts were escalated before production or participant travel occurred.

The study team also established weekly capacity reviews, defined scheduling cut-off points, and maintained contingency options for participants at risk of missing protocol-defined windows.

Results: Greater Resilience and Continued Study Execution

Vantage BioTrials’ intervention converted a recurring operational disruption into a controlled continuity strategy.

Following implementation:

        §   A second qualified manufacturing source became available to support study conduct;

        §   Single-source manufacturing dependency was materially reduced;

        §   Available production and scheduling flexibility increased by approximately 90%;

        §   Manufacturing and scanner capacity were managed through an integrated planning process;

        §   No additional participant withdrawals attributable to single-source manufacturing dependency occurred during the remaining study period;

        §   The study continued without a prolonged enrollment suspension;

        §   Potential scheduling conflicts were identified earlier, before participant travel and product production; and

        §   The Sponsor gained clearer visibility into capacity constraints, mitigation status, and residual operational risk.

The intervention did not eliminate the inherent complexity of radiopharmaceutical manufacturing and imaging. Instead, it gave the Sponsor and study team the governance, contingency capacity, and operational visibility required to manage that complexity without allowing individual disruptions to evolve into a broader study failure.

Sponsor Value: Anticipating Risk Before It Becomes a Timeline Failure

This case illustrates why radiopharmaceutical trial readiness must be evaluated across the complete participant-treatment pathway.

Manufacturing availability alone does not establish operational feasibility. Production, quality-control testing, batch release, product administration, participant availability, scanner access, specialized personnel, and protocol-defined imaging windows must function as one coordinated system.

Vantage BioTrials identified the single-source dependency before it materialized, maintained visibility of the risk during study conduct, and acted decisively when the operating assumptions no longer remained acceptable. By combining structured escalation, cross-functional governance, second-source qualification, and integrated capacity planning, Vantage BioTrials helped the Sponsor preserve study continuity and reduce the risk of further participant and timeline disruption.

Key Takeaway

In radiopharmaceutical trials, a CRO must do more than track enrollment and respond to individual site issues. It must understand how manufacturing, quality release, imaging, and clinical operations interact, and recognize when an isolated event signals a systemic risk.

Vantage BioTrials applies Quality by Design and risk-based clinical oversight to:

        §   Identify fragile operational dependencies during planning;

        §   Challenge assumptions that could place participants or timelines at risk;

        §   Establish clear risk ownership and escalation thresholds;

        §   Coordinate controlled, cross-functional mitigation strategies; and

       §   Maintain alignment among manufacturing, imaging, sites, and clinical operations throughout study conduct.

Planning a radiopharmaceutical study or experiencing manufacturing, imaging, or site-capacity constraints?

Contact Vantage BioTrials to assess your operational readiness and develop a risk-based clinical execution strategy.